MedCity Pivot Podcast: How Fujifilm Tackled An Existential Crisis
Fujifilm went from being the no. 1 camera film company to seeing sales tumble as…
MedCity Pivot Podcast: How Fujifilm Tackled An Existential Crisis
Fujifilm went from being the no. 1 camera film company to seeing sales tumble as consumers switched to digital cameras. Lars Petersen, CEO of the company’s biotechnologies business, explains how the company pivoted to becoming a partner of the life sciences industry. The post MedCity Pivot Podcast: How Fujifilm Tackled An Existential Crisis appeared first…
Top-Paying Healthcare Settings for Travel Nurses and How to Land Them
[Sponsored] If you’ve been researching current high-paying jobs in trauma centers or wondering which agencies have the best-paying contracts right now, you’re already thinking like a strategic travel nurse. The post Top-Paying Healthcare Settings for Travel Nurses and How to Land Them appeared first on MedCity News.
AI Is Fueling a New Arms Race in Healthcare: Here’s How We Stop It
Rather than using AI to compete, we must design AI to collaborate. As the regulatory landscape evolves and industry pledges push for real-time, electronic, and transparent authorizations, the imperative is clear: technology must bridge the payer-provider divide, not widen it. The post AI Is Fueling a New Arms Race in Healthcare: Here’s How We Stop…
Red Light Therapy’s Regulatory Implications
For consumers and clinicians the difference between “FDA-cleared,” “FDA-registered,” and general wellness products is not always obvious. Clear communication about intended use and supporting evidence is essential for maintaining trust. The post Red Light Therapy’s Regulatory Implications appeared first on MedCity News.
Why CREST-2 Trial Results Should Inform, Not Replace, Clinical Judgment
While CREST-2 can stand as a guideline for understanding ACS therapies in case-by-case scenarios, it’s critical that trial conclusions do not replace clinical judgment and years of previous research. The post Why CREST-2 Trial Results Should Inform, Not Replace, Clinical Judgment appeared first on MedCity News.
Inside the High-Stakes Corporate Fight Over Feeding Preterm Babies
In 2013, a scientist at Abbott Laboratories saw study results with potentially big implications for the company’s profits and the lives of some of the world’s most fragile people: preterm infants. The upshot, she wrote in an email: Babies fed rival Mead Johnson Nutrition’s acidified liquid human milk fortifier — a nutritional supplement used in…
She Owed Her Insurer a Nickel, So It Canceled Her Coverage
Last summer, Lorena Alvarado Hill received a series of unexpected medical bills. A teacher’s aide in Melbourne, Florida, Hill is a single mom who works shifts at J.Crew on the weekends to send her daughter to college. Hill and her mother, who lives with her, had been enrolled in an insurance plan through HealthFirst. Hill…
Adventures in health care billing. My $51.96 zit co-insurance
By MATTHEW HOLT I know my many fans love me delving into the world of why we get seemingly incorrect trivial bills in health care, and what they all mean. The long telenovella of the $39.94 bill from Labcorp is as yet stalled with One Medical apparently resubmitting the original claim with the new preventative…
Everlywell, Jona Team Up to Expand Access to Gut Microbiome Test
Through a new partnership, consumers nationwide can access Jona’s gut microbiome test on Everlywell’s platform. The post Everlywell, Jona Team Up to Expand Access to Gut Microbiome Test appeared first on MedCity News.
FDA Approval Makes Rocket Pharma Gene Therapy the First for Ultra-Rare Immune Disorder
Rocket Pharmaceuticals received FDA approval for Kresladi, a gene therapy developed to treat leukocyte-adhesion deficiency type 1, an inherited immunodeficiency that can become fatal to infants and young children. Kresladi is the first gene therapy for this ultra-rare disease and the first commercial product for Rocket. The post FDA Approval Makes Rocket Pharma Gene Therapy…
